Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones

Rhea-AI Summary

Atossa Therapeutics (NASDAQ:ATOS) has appointed Janet R. Rea, MSPH as Senior Vice President, R&D. This strategic hire brings over 20 years of clinical development and regulatory expertise to accelerate the development of (Z)-endoxifen, the company's lead product candidate for breast cancer treatment and prevention.

Ms. Rea, who previously served at Atossa, returns with significant experience in securing regulatory approvals, including her role in the approval of FluBlok® at Protein Sciences. Her prior work at Atossa involved securing regulatory clearance for (Z)-endoxifen clinical studies in Australia, the US, and Sweden.

In her new role, Ms. Rea will focus on upcoming FDA submissions and defining the pathway to commercialization for (Z)-endoxifen across multiple indications.

News Market Reaction

+5.67%

5 alerts

+5.67% News Effect

+$6M Valuation Impact

$120M Market Cap

1.0x Rel. Volume

On the day this news was published, ATOS gained 5.67%, reflecting a notable positive market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $6M to the company's valuation, bringing the market cap to $120M at that time.

Data tracked by StockTitan Argus on the day of publication.

Veteran development leader with successful regulatory approvals record returns to lead late-stage clinical and regulatory programs to address multiple unmet clinical needs

SEATTLE, Oct. 1, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS; "Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, announces the appointment of Janet R. Rea, MSPH to its newly created position Senior Vice President, R&D.  Ms. Rea brings more than two decades of strategic research and clinical development expertise, with a success record for regulatory approvals, to oversee late-stage (Z)-endoxifen programs with near term priorities that include upcoming FDA submissions, interactions, and defining pathway to commercialization.  Atossa Therapeutics is a clinical-stage biopharmaceutical company developing (Z)-endoxifen for innovative therapeutic applications.

Ms. Rea most recently served as a consultant to a variety of biopharmaceutical companies.  She has held senior development leadership roles for AVM Biotechnology (COO, SVP), Atossa Therapeutics, TPI Therapeutics, and Protein Sciences (now Glaxo), where she played a key role leading to the approval of FluBlok^®, an innovative rDNA egg-free influenza vaccine.  She was also an Assistant Professor at the University of Washington, Department of Pharmacy. Prior to that, she secured IND clearance for what is now Exondys 51 (eteplirsen) on behalf of AVI Biopharma (Sarepta). Having previously served as Senior Vice President, Regulatory, Quality, and Clinical Affairs at Atossa, she secured regulatory clearance for and executed clinical studies of (Z)-endoxifen in Australia, the US, and Sweden, which have been the cornerstone of the breast cancer treatment programs. Ms. Rea now returns to Atossa to focus on further advancing Atossa's pipeline, contributing to the development and delivery of new treatments.

"Janet's extensive experience in strategic regulatory and clinical development pathways, particularly in getting programs successfully through approval processes, aligns perfectly with our mission to bring transformative treatments," said Dr. Steven Quay, Atossa Therapeutics Chief Executive Officer. "We are laser-focused on bringing our lead product candidate, (Z)-endoxifen, to market to address the large clinical need across multiple indications. Janet combines approval-path experience with hands-on execution – exactly what we need to propel our programs forward."

For over 20 years, Ms. Rea has built an impressive career with leadership positions in the clinical development and execution of regulatory strategies. She has directed cross-functional teams, led regulatory submissions in the US and internationally, and managed comprehensive clinical development programs including in oncology, biopharmaceuticals, as well as viral and cardiovascular diseases.  Her expertise in aligning clinical strategy with regulatory and commercial goals are supportive to Atossa's growth.

"Atossa is at an exciting inflection point.  I am thrilled to rejoin the team advancing promising (Z)-endoxifen therapies to market," said Ms. Rea.

About Atossa Therapeutics

Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions. The Company's lead product candidate, (Z)-endoxifen, is a highly potent SERM/D designed for use across the breast cancer spectrum, including risk-reduction, and treatment in the neoadjuvant, adjuvant, and metastatic settings. Atossa is committed to advancing its robust clinical research programs to improve patient outcomes while creating sustainable value for shareholders. For more information, visit atossatherapeutics.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/atossa-therapeutics-names-janet-r-rea-msph-as-senior-vice-president-rd-to-accelerate-z-endoxifen-toward-key-regulatory-milestones-302572041.html

SOURCE Atossa Therapeutics Inc

FAQ

Who is Janet R. Rea and what is her new role at Atossa Therapeutics (NASDAQ:ATOS)?

Janet R. Rea, MSPH, has been appointed as Senior Vice President, R&D at Atossa Therapeutics. She brings over 20 years of strategic research and clinical development expertise, with a successful record in regulatory approvals.

What is Janet Rea's previous experience with Atossa Therapeutics (ATOS)?

She previously served as Senior Vice President, Regulatory, Quality, and Clinical Affairs at Atossa, where she secured regulatory clearance for and executed clinical studies of (Z)-endoxifen in Australia, the US, and Sweden.

What are Janet Rea's primary responsibilities at Atossa Therapeutics (ATOS)?

Her primary responsibilities include overseeing late-stage (Z)-endoxifen programs, managing upcoming FDA submissions and interactions, and defining the pathway to commercialization.

What notable achievements has Janet Rea accomplished in her career?

She played a key role in the approval of FluBlok® at Protein Sciences (now Glaxo) and secured IND clearance for what became Exondys 51 at AVI Biopharma (Sarepta), among other regulatory and development successes.